Viacheslav Iremashvili, Murugesan Manoharan, Liset Pelaez, Daniel L. Rosenberg and Mark S. Soloway Clinically significant Gleason sum upgrade Cancer 118
Version of Record online: 5 JUL 2011 | DOI: 10.1002/cncr.26306
The existing nomograms were limited in their capacity to predict the risk of upgrading in patients who had prostate cancer with a biopsy Gleason sum ≤6. Therefore, the authors of this report concluded that, from a practical perspective, such nomograms are not sufficiently accurate to be used safely for clinical decision-making.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field